Notably, immunohistochemistry-assessed PD-L1 expression was found in 4/18 patients (22.2%) with histologically confirmed PC (10), thus suggesting that immune checkpoint blockade may have a rationale in the treatment of this type of tumours. This evidence concerns the gene CD274 and pachyonychia congenita.